Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19558728 | 0.83 | CYP2E1 (0.37) | — | |
| SCHEMBL418112 | 0.82 | MITF (0.33) | ALOX5PTGS1PTGS2CHRM2CHRM4 | |
| SCHEMBL19558652 | 0.77 | MITF (0.33) | — | |
| SCHEMBL2152164 | 0.76 | TDP1 (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12338361 | 0.76 | SLC6A4 (0.36) | ALOX5PTGS1PTGS2CHRM2CHRM4 | |
| SCHEMBL23890860 | 0.74 | AR (0.30) | — | |
| SCHEMBL45858 | 0.72 | — | — | |
| SCHEMBL14034345 | 0.72 | NQO1 (0.31) | — | |
| SCHEMBL25270446 | 0.72 | CYP1A2 (0.36) | ALOX5PTGS1PTGS2 | |
| SCHEMBL27591611 | 0.71 | ALOX5 (0.33) | ALOX5PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099252-A1 | NOVEL LAULIMALIDE ANALOGUES AS THERAPEUTIC AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
| US-20080280973-A1 | Laulimalide Analogues as Therapeutic Agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280973-A1 | Laulimalide Analogues as Therapeutic Agents | TUBB6, MAN2B1, TUBB1 | ALOX5 3646/4885PTGS1 4287/4885PTGS2 4451/4885 |
| US-20090099252-A1 | NOVEL LAULIMALIDE ANALOGUES AS THERAPEUTIC AGENTS | TUBB6, TUBB1, TUBA1C | ALOX5 3842/4885PTGS1 4247/4885PTGS2 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.